Cargando…

Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives

Metastatic colorectal cancer (mCRC) is a prevalent disease for which combination cytotoxic chemotherapy is the mainstay of treatment. With the use of targeted therapy, including anti-angiogenic agents, there have been significant improvements in overall outcome of patients with mCRC. Bevacizumab, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bupathi, Manojkumar, Ahn, Daniel H, Bekaii-Saab, Tanios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300250/ https://www.ncbi.nlm.nih.gov/pubmed/28190957 http://dx.doi.org/10.2147/GICTT.S97740

Ejemplares similares

New developments in the treatment of metastatic gastric cancer: focus on trastuzumab
por: Rose, Jeffrey S, et al.
Publicado: (2011)

The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies
por: Ahn, Daniel H., et al.
Publicado: (2017)

Response to Drs Von Hoff and Renschler
por: Ahn, Daniel H., et al.
Publicado: (2017)

Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements
por: Walden, Daniel, et al.
Publicado: (2022)

Therapeutic Targeting Strategies of Cancer Stem Cells in Gastrointestinal Malignancies
por: Sonbol, Mohamad B., et al.
Publicado: (2019)

Management of Venous Thromboembolism in Patients with Advanced Gastrointestinal Cancers: What Is the Role of Novel Oral Anticoagulants?
por: Martin, Ludmila Katherine, et al.
Publicado: (2012)

Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial
por: Mettu, Niharika B., et al.
Publicado: (2022)

Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma
por: Ahn, Daniel H., et al.
Publicado: (2018)

CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer
por: Wu, Christina, et al.
Publicado: (2012)

Identifying and targeting cancer stem cells in the treatment of gastric cancer
por: Bekaii‐Saab, Tanios, et al.
Publicado: (2017)

Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report
por: So, Brian J, et al.
Publicado: (2008)

Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives
por: Woo, Wonhee, et al.
Publicado: (2019)

Practical considerations in the use of regorafenib in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2020)

Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial
por: Lipsyc-Sharf, Marla, et al.
Publicado: (2022)

Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectives
por: Bupathi, Manojkumar, et al.
Publicado: (2014)

Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes
por: Bekaii-Saab, Tanios S, et al.
Publicado: (2023)

Update to “Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors”
por: Zhu, Mojun, et al.
Publicado: (2022)

Adjuvant therapy for pancreas cancer in an era of value based cancer care
por: Ahn, Daniel H., et al.
Publicado: (2015)

Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors
por: Ahn, Daniel H., et al.
Publicado: (2015)

Immunological predictors of overall survival in treatment naïve metastatic pancreatic cancer patients
por: Farren, Matthew R, et al.
Publicado: (2015)

Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States
por: Barzi, Afsaneh, et al.
Publicado: (2020)

Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer
por: Chen, Li-Tzong, et al.
Publicado: (2019)

Using Naïve Bayesian Analysis to Determine Imaging Characteristics of KRAS Mutations in Metastatic Colon Cancer
por: Pershad, Yash, et al.
Publicado: (2017)

Impact of Tumor Location and Variables Associated With Overall Survival in Patients With Colorectal Cancer: A Mayo Clinic Colon and Rectal Cancer Registry Study
por: Wang, Cassia B., et al.
Publicado: (2019)

Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure–safety analyses in patients with metastatic pancreatic cancer
por: Brendel, Karl, et al.
Publicado: (2021)

Frontline therapy for advanced hepatocellular carcinoma: an update
por: Akce, Mehmet, et al.
Publicado: (2022)

Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives
por: Costa, Ricardo, et al.
Publicado: (2016)

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer
por: Di Bartolomeo, Maria, et al.
Publicado: (2015)

Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series
por: Bupathi, Manojkumar, et al.
Publicado: (2017)

Bevacizumab in the therapy for refractory metastatic colorectal cancer
por: Mulcahy, Mary F
Publicado: (2008)

Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses
por: Haraldsdottir, Sigurdis, et al.
Publicado: (2016)

Maintenance Therapy in First-Line Gastric and Gastroesophageal Junction Adenocarcinoma: A Retrospective Analysis
por: Walden, Daniel, et al.
Publicado: (2021)

Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer
por: Zoratto, Federica, et al.
Publicado: (2012)

Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer
por: Ahn, Daniel H., et al.
Publicado: (2015)

A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma
por: Bekaii-Saab, Tanios, et al.
Publicado: (2006)

Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer
por: Stein, Alexander, et al.
Publicado: (2015)

Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab
por: Epistolio, Samantha, et al.
Publicado: (2021)

The Impact of Bevacizumab and Chemotherapy on Quality of Life in Metastatic Colorectal Cancer Patients
por: Moisuc, Diana Cornelia, et al.
Publicado: (2023)

Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model
por: Kaumaya, Pravin T. P., et al.
Publicado: (2020)

Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma
por: Storandt, Michael H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p70q8r2gaaun5hq70v3cci647r